Austin A. Whitman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Austin A. Whitman has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Attila T. Szenasi
Lineberger Comprehensive Cancer Center, University of North Carolina
1 shared publication- Charles M. Perou
University of North Carolina at Chapel Hill 1 Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina
1 shared publication Christine Hnc Thai
Lineberger Comprehensive Cancer Center, University of North Carolina
1 shared publication- Denis O. Okumu
University of North Carolina at Chapel Hill 2 Department of Pharmacology Chapel Hill, North Carolina
1 shared publication - Elizabeth Brunk
University of North Carolina at Chapel Hill
1 shared publication Gary L. Johnson
Lineberger Comprehensive Cancer Center, University of North Carolina
1 shared publication
Latest Publications
- Open Access
Kinase Plasticity with Vandetanib Treatment Enhances Sensitivity to Tamoxifen in Estrogen Receptor Positive Breast Cancer
Resistance to endocrine therapy (ET) is common in estrogen receptor-positive (ER+) breast cancer. Multiple studies have demonstrated that upregulation of MAPK signaling pathways contributes to ET resistance. Herein we show that vandetanib treatment suppresses MAPK signaling and enhances sensitivity to ET across ET-sensitive and ET-resistant ER+ cell lines and patient derived organoids. Vandetanib treatment reprograms transcription toward a less proliferative, more estrogen responsive, Luminal-A like state by enriching ERα chromatin binding at canonical estrogen response elements. Multiplexed kinase inhibitor beads-mass spectrometry (MIB/MS) revealed kinase network reprogramming, including upregulation of PI3K and HER2 activity, as shared adaptive resistance mechanisms to vandetanib treatment. Co-treatment with the HER2 inhibitor lapatinib, further enhanced sensitivity to vandetanib. Using an operating room-to-laboratory short-term ex-vivo assay coupled to single-cell RNA sequencing, we demonstrate conserved gene expression changes in primary tumor cells, including increased HER2 activity signatures, following vandetanib treatment. Vandetanib sensitivity signatures were generated from cell line and primary human tumor cells which correlate with vandetanib sensitivity in ER+ patient-derived organoid and xenograft models. Future clinical trials of vandetanib in ER+ breast cancer should include rationally designed co-treatments based on adaptive resistance pathways, including HER2, and evaluate response signatures as biomarkers predicting patients most likely to benefit. SIGNIFICANCE: Vandetanib enhances sensitivity to tamoxifen in ER+ breast cancer by reprograming ERα gene regulation and kinase signaling networks which define gene expression signatures associated with response and identify targetable adaptive resistance pathways.
Open AccessKinase Plasticity with Vandetanib Treatment Enhances Sensitivity to Tamoxifen in Estrogen Receptor Positive Breast Cancer
Resistance to endocrine therapy (ET) is common in estrogen receptor-positive (ER+) breast cancer. Multiple studies have demonstrated that upregulation of MAPK signaling pathways contributes to ET resistance. Herein we show that vandetanib treatment suppresses MAPK signaling and enhances sensitivity to ET across ET-sensitive and ET-resistant ER+ cell lines and patient derived organoids. Vandetanib treatment reprograms transcription toward a less proliferative, more estrogen responsive, Luminal-A like state by enriching ERα chromatin binding at canonical estrogen response elements. Multiplexed kinase inhibitor beads-mass spectrometry (MIB/MS) revealed kinase network reprogramming, including upregulation of PI3K and HER2 activity, as shared adaptive resistance mechanisms to vandetanib treatment. Co-treatment with the HER2 inhibitor lapatinib, further enhanced sensitivity to vandetanib. Using an operating room-to-laboratory short-term ex-vivo assay coupled to single-cell RNA sequencing, we demonstrate conserved gene expression changes in primary tumor cells, including increased HER2 activity signatures, following vandetanib treatment. Vandetanib sensitivity signatures were generated from cell line and primary human tumor cells which correlate with vandetanib sensitivity in ER+ patient-derived organoid and xenograft models. Future clinical trials of vandetanib in ER+ breast cancer should include rationally designed co-treatments based on adaptive resistance pathways, including HER2, and evaluate response signatures as biomarkers predicting patients most likely to benefit. SIGNIFICANCE: Vandetanib enhances sensitivity to tamoxifen in ER+ breast cancer by reprograming ERα gene regulation and kinase signaling networks which define gene expression signatures associated with response and identify targetable adaptive resistance pathways.